Literature DB >> 23069701

Establishment of a Shigella sonnei human challenge model in Thailand.

Ladaporn Bodhidatta1, Punnee Pitisuttithum, Supat Chamnanchanant, Karen T Chang, Dilara Islam, Valai Bussaratid, Malabi M Venkatesan, Thomas L Hale, Carl J Mason.   

Abstract

In order to establish a human challenge model of Shigella related disease for vaccine testing, a dose-escalating inpatient trial was performed. Three groups of 12 healthy adult volunteers were orally challenged with 93,440 and 1680 CFU of Shigella sonnei strain 53G. Subjects were admitted to the Vaccine Trial Centre (VTC) at Mahidol University in Bangkok, Thailand. The primary purpose of this study was to identify the dose of S. sonnei 53G required to elicit clinical disease in at least 70% of Thai adult subjects. At the highest dose of 1680 CFU, the attack rate was 75%, while at the two lower doses, the attack rate was approximately 50%. This human challenge model, which is the first of its kind in an endemic region, will provide an opportunity for S. sonnei vaccine evaluation in endemic populations. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23069701      PMCID: PMC3732056          DOI: 10.1016/j.vaccine.2012.09.061

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  24 in total

1.  Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers.

Authors:  Nadav Orr; David E Katz; Jacob Atsmon; Paull Radu; Miri Yavzori; Tamar Halperin; Tamar Sela; Raid Kayouf; Zivit Klein; Ruhama Ambar; Dani Cohen; Marcia K Wolf; Malabi M Venkatesan; Thomas L Hale
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

2.  Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection.

Authors:  H L DuPont; R B Hornick; M J Snyder; J P Libonati; S B Formal; E J Gangarosa
Journal:  J Infect Dis       Date:  1972-01       Impact factor: 5.226

3.  The response of man to virulent Shigella flexneri 2a.

Authors:  H L DuPont; R B Hornick; A T Dawkins; M J Snyder; S B Formal
Journal:  J Infect Dis       Date:  1969-03       Impact factor: 5.226

Review 4.  Shigellosis update: advancing antibiotic resistance, investment empowered vaccine development, and green bananas.

Authors:  Margaret Kosek; Pablo Peñataro Yori; Maribel Paredes Olortegui
Journal:  Curr Opin Infect Dis       Date:  2010-10       Impact factor: 4.915

5.  Estimating the burden of shigellosis in Thailand: 36-month population-based surveillance study.

Authors:  Pornthip Chompook; Seksun Samosornsuk; Lorenz von Seidlein; Supot Jitsanguansuk; Nunta Sirima; Sanit Sudjai; Prasitchai Mangjit; Deok Ryun Kim; Jeremy G Wheeler; Jim Todd; Hyejon Lee; Mohammad Ali; John Clemens; Pramuan Tapchaisri; Wanpen Chaicumpa
Journal:  Bull World Health Organ       Date:  2005-11-10       Impact factor: 9.408

6.  Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection.

Authors:  S Barnoy; S Baqar; R W Kaminski; T Collins; K Nemelka; T L Hale; R T Ranallo; M M Venkatesan
Journal:  Vaccine       Date:  2011-05-17       Impact factor: 3.641

Review 7.  Arthritis associated with enteric infection.

Authors:  J S Hill Gaston; Mark S Lillicrap
Journal:  Best Pract Res Clin Rheumatol       Date:  2003-04       Impact factor: 4.098

8.  Antimicrobial susceptibility of Shigella isolates in eight Asian countries, 2001-2004.

Authors:  Chen-Yen Kuo; Lin-Hui Su; Jennifer Perera; Celia Carlos; Ban Hock Tan; Gamini Kumarasinghe; Thomas So; Pham Hung Van; Anan Chongthaleong; Jae-Hoon Song; Cheng-Hsun Chiu
Journal:  J Microbiol Immunol Infect       Date:  2008-04       Impact factor: 4.399

Review 9.  Shigellosis: the current status of vaccine development.

Authors:  Mi-Na Kweon
Journal:  Curr Opin Infect Dis       Date:  2008-06       Impact factor: 4.915

10.  Comparative antibiotic resistance of diarrheal pathogens from Vietnam and Thailand, 1996-1999.

Authors:  Daniel W Isenbarger; Charles W Hoge; Apichai Srijan; Chittima Pitarangsi; Niyada Vithayasai; Ladaporn Bodhidatta; Kimberly W Hickey; Phung Dac Cam
Journal:  Emerg Infect Dis       Date:  2002-02       Impact factor: 6.883

View more
  14 in total

Review 1.  Systems vaccinology: Enabling rational vaccine design with systems biological approaches.

Authors:  Thomas Hagan; Helder I Nakaya; Shankar Subramaniam; Bali Pulendran
Journal:  Vaccine       Date:  2015-04-06       Impact factor: 3.641

2.  Ethical challenges posed by human infection challenge studies in endemic settings.

Authors:  Michael J Selgelid; Euzebiusz Jamrozik
Journal:  Indian J Med Ethics       Date:  2018-09-18

Review 3.  Controlled Human Infection Models To Accelerate Vaccine Development.

Authors:  Robert K M Choy; A Louis Bourgeois; Christian F Ockenhouse; Richard I Walker; Rebecca L Sheets; Jorge Flores
Journal:  Clin Microbiol Rev       Date:  2022-07-06       Impact factor: 50.129

Review 4.  Escherichia coli Residency in the Gut of Healthy Human Adults.

Authors:  Jonathan N V Martinson; Seth T Walk
Journal:  EcoSal Plus       Date:  2020-09

Review 5.  Human infection challenge studies in endemic settings and/or low-income and middle-income countries: key points of ethical consensus and controversy.

Authors:  Euzebiusz Jamrozik; Michael J Selgelid
Journal:  J Med Ethics       Date:  2020-05-07       Impact factor: 2.903

6.  Ethics of alternative trial designs and methods in low-resource settings.

Authors:  Rieke van der Graaf; Phaik Yeong Cheah
Journal:  Trials       Date:  2019-12-19       Impact factor: 2.279

Review 7.  Control of Invasive Salmonella Disease in Africa: Is There a Role for Human Challenge Models?

Authors:  Malick M Gibani; Celina Jin; Thomas C Darton; Andrew J Pollard
Journal:  Clin Infect Dis       Date:  2015-11-01       Impact factor: 9.079

8.  Clinical Trial of an Oral Live Shigella sonnei Vaccine Candidate, WRSS1, in Thai Adults.

Authors:  Punnee Pitisuttithum; Dilara Islam; Supat Chamnanchanunt; Nattaya Ruamsap; Patchariya Khantapura; Jaranit Kaewkungwal; Chatporn Kittitrakul; Viravarn Luvira; Jittima Dhitavat; Malabi M Venkatesan; Carl J Mason; Ladaporn Bodhidatta
Journal:  Clin Vaccine Immunol       Date:  2016-07-05

9.  A framework for Controlled Human Infection Model (CHIM) studies in Malawi: Report of a Wellcome Trust workshop on CHIM in Low Income Countries held in Blantyre, Malawi.

Authors:  Stephen B Gordon; Jamie Rylance; Amy Luck; Kondwani Jambo; Daniela M Ferreira; Lucinda Manda-Taylor; Philip Bejon; Bagrey Ngwira; Katherine Littler; Zoe Seager; Malick Gibani; Markus Gmeiner; Meta Roestenberg; Yohannie Mlombe
Journal:  Wellcome Open Res       Date:  2017-08-24

10.  Dominant serotype distribution and antimicrobial resistance profile of Shigella spp. in Xinjiang, China.

Authors:  Hongbo Liu; Binghua Zhu; Shaofu Qiu; Yidan Xia; Beibei Liang; Chaojie Yang; Nian Dong; Yongrui Li; Ying Xiang; Shan Wang; Jing Xie; Muti Mahe; Yansong Sun; Hongbin Song
Journal:  PLoS One       Date:  2018-04-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.